STAT3 is a transcription factor that is constitutively active in castration-resistant prostate cancer. A fungal metabolite called galiellalactone inhibits STAT3 signaling in prostate cancer cells with active STAT3, suggesting the molecule has potential as a targeted therapy. In this Paper of the Week, a team led by Rebecka Hellsten at Lund University in Sweden looked more closely at the molecular mechanism of the action of galiellalactone on STAT3. The investigators demonstrated that galiellalactone is a cysteine-reactive inhibitor that covalently binds to one or several cysteines on STAT3. This binding blocks STAT3 from binding to DNA. The authors conclude, "This further validates galiellalactone as a promising direct STAT3 inhibitor for treatment of castration-resistant prostate cancer." DOI 10.1074/jbc.P114.564252 15979 Galiellalactone bound to STAT3. Surface (gray) and ribbon (turquoise ϭ coiled-coil domain, purple ϭ linker domain, red ϭ DNA binding domain) representation of STAT3 monomer bound to DNA (orange) with the three cysteine residues alkylated by galiellalactone labeled (green with sulfur in yellow).
